BIOSENSOR DISEASE AND INFECTION SCREENING
The disclosed invention includes methods to employ wearable biosensing devices to accomplish the following: 1) screen for the presence of a disease or infection, including pre-symptomatic detection, and determination of the type (e.g., viral, bacterial, or fungal) of disease or infection present; 2) confirm the antigen and monitor the progress of an active infection; and 3) monitor the efficacy of a treatment program for a disease or infection. Such methods rely on the detection, in sweat or other biofluids, of proteins, nucleotides, DNA polymerases, proteases, group-specific antigens, antibodies, cytokines, or other molecules, that are produced by the body as part of the innate or adaptive immune responses to an infectious agent, or the infectious agent itself, its products, or derivatives. Some embodiments comprise a method of using such a biosensing device as a biosentinel against biological threats.
1 . A method to screen for an infection by an antigen, comprising:
using a biosensing device that is configured to be worn on an individual's skin to take one or more measurements of an analyte in a biofluid sample, wherein the analyte is one of the following: a solute indicating the individual's innate immune response to the antigen; a solute indicating the individual's adaptive immune response to the antigen; a solute produced by the antigen; and at least a portion of the antigen;
developing a baseline value for the one or more analyte measurements that correlates to a healthy condition for the individual;
comparing the one or more analyte measurements to the baseline value to determine if the infection is indicated; and
transmitting an alert message to a device user communicating a status of the infection.
2 . The method of claim 1 , wherein the status of the infection is determined using one or more of the following information categories: a value that correlates to a healthy concentration of the analyte in the biofluid of the individual; a value that correlates to a healthy concentration of the analyte in the biofluid of a plurality of healthy individuals; a set of relevant physical characteristics of the individual; a geographic location of the individual; a previous geographic location of the individual; an exposure of the antigen to the individual; an outbreak of a disease caused by the antigen; one or more characteristics of the antigen; a presence of vectors that carry the antigen; and a time of year.
3 . The method of claim 1 , further comprising determining a type of the infection, wherein the type is one of the following: a viral infection; and a bacterial infection.
4 . The method of claim 3 , further comprising: taking one or more measurements of the following analytes in the biofluid sample: IL-6, TNF-related apoptosis-inducing ligand (TRAIL), C-reactive protein, and IP-10.
5 . The method of claim 3 , further comprising determining whether an infection is a viral infection by measuring biofluid concentrations of the following analytes: IL-6, TNF-related apoptosis-inducing ligand (TRAIL), and TNF-α.
6 . The method of claim 3 , further comprising determining whether an infection is a viral infection by measuring biofluid concentrations of one or more of the following analytes: TNF-α; IL-1; IL-6; IL-12; IL-15; IL-18; IFN-α; IFN-β; IFN-γ; TNF-related apoptosis-inducing ligand (TRAIL); a microRNA; a cell adhesion molecule; a circulating host protein; an antibody; a T-cell; a heat shock protein; an RNA molecule; a DNA molecule; a virus; a viral protein; a glycoprotein; a capsid protein; a capsomere; a lipid envelope; and a viral bud.
7 . The method of claim 3 , further comprising determining whether an infection is a bacterial infection by measuring biofluid concentrations of the following analytes: IL-6, procalcitonin (PCT), and C-reactive protein.
8 . The method of claim 3 , further comprising determining whether an infection is a bacterial infection by measuring biofluid concentrations of one or more of the following analytes: IP-10; IL-6; procalcitonin (PCT); C-reactive protein; a microRNA; a cell adhesion molecule; a circulating host protein; an antibody; a T-cell; a heat shock protein; RNA; DNA; a bacterium, a bacterial component; a bacterial product; a bacterial endotoxin; a bacterial exotoxin; and a lipopolysaccharide (LPS).
9 . The method of claim 1 , further comprising developing a disease signature that correlates to an infection by the antigen.
10 . The method of claim 1 , further comprising determining if an infection is indicated within one of the following time periods after the individual is exposed to the antigen: less than 24 hours; less than 48 hours; less than 72 hours; less than one week; and less than two weeks.
11 . The method of claim 3 , wherein the type further includes the following: a parasitic infection; and a fungal infection.
12 . The method of claim 11 , further comprising determining whether an infection is a fungal infection by measuring biofluid concentrations of one or more of the following analytes: a microRNA; a cell adhesion molecule; a circulating host protein; an antibody; a T-cell; a heat shock protein; RNA; DNA; a fungus, a fungal component; and a fungal product.
13 . The method of claim 1 , wherein the device is used to facilitate biosentinel applications, further comprising:
identifying the antigen as a biological threat;
configuring the device to screen for the antigen;
deploying the device to a plurality of individuals at risk for exposure to the antigen;
relaying the alert message to a device user tasked to respond to the biological threat.
14 . A method for using a biosensing device configured to be worn on an individual's skin to monitor an infection by a specific antigen, comprising:
taking at least one measurement of the individual's biofluid for at least one analyte, where the analyte is one or more of the following: a molecule indicating the individual's innate immune response to the antigen; a molecule indicating the individual's adaptive immune response to the antigen; a molecule produced by the antigen; and at least a portion of the antigen;
developing a comparison value for the analyte measurement that correlates to a previous physical condition for the individual;
comparing the analyte measurement to the baseline to determine the infection status; and
transmitting an alert message to a device user relaying the infection status.
15 . The method of claim 14 , wherein the infection status includes at least one of the following: an infection maturity; an infection severity; and an effectiveness of an infection treatment.